#227: Unique Global Regulatory Considerations and Drug Development Incentives in Rare Disease and Orphan Drug Development
Chair
Patient Advocate / Secretary, Canadian Organization For Rare Disorders (CORD)
Maureen Smith’s M.Ed. (Educational Psychology) interest in patient advocacy stems from a rare disease diagnosis at the age of 8. She is the Secretary of the Canadian Organization for Rare Disorders (CORD), co-chair of the Rare/Orphan Disease program track for the Drug Information...
Read More →
Speakers IP
Senior Research Scientist, UBC: An Express Scripts Company
Irene Pan, MSc, is a Senior Research Scientist with UBC: An Express Scripts Company. With over 12 years of clinical research experience, Ms. Pan has conducted numerous studies in a wide range of therapeutic indications including ophthalmology, neurology, cardiology, oncology and respiratory...
Read More →
Director, Global Regulatory Affairs, Pfizer Inc
15 years of experience across public and government (FDA) sectors with an MBA in biotechnology and an MS in biochemistry. Global experience leading reg strategy with drugs (NCE, line extensions, drug: drug codev, biologic products, and combination products [drug: device]), in all...
Read More →
Tuesday June 28, 2016 10:30am - 11:30am EDT
103C
Pennsylvania Convention Center 1101 Arch Street, Philadelphia, PA 19107 USA
Trk 17: Rare-Orphan Diseases,
Session
- Credit Type ACPE, CME, IACET, RN
- Audience Intermediate
- Featured Topics Approval Pathways, Regulatory Harmonization-Convergence
- Interest Area Rare - Orphan Diseases, Regulatory Affairs
- format json
- Interest Area Rare / Orphan Diseases,Regulatory Affairs
- Featured Topics Approval Pathways,Regulatory Harmonization/Convergence
- Credit Type ACPE, CME, IACET, RN
- Tags Session